In an early morning press release, Moderna announced that its FDA hearing will be held a week later, on December 17. AstraZeneca has announced an average efficacy rate of 70% for its shot and as much as 90% for a subgroup of trial participants who got a half dose, followed by a full dose.
Shares in covid vaccine maker Moderna rallied by more than 10pc after the company released another tranche of data showing that the jab is effective and announced it was submitting the results to regulators for speedy approval.
Pfizer said its vaccine was 95% effective in the final analysis, but it had a different number of COVID-19 cases in its trial, so the percentages shouldn't be compared head-to-head without context, experts say.
Dr Zaks said he was emotional after seeing the results. This was a key secondary endpoint, which analyzed severe cases of COVID-19 and included 30 severe cases.
They will meet on December 10 to review Pfizer's data. Additional details about the trial will become available through the FDA's review process, which the agency has pledged will be transparent to the public.
The covid vaccines have shown over 90% efficacy to prevent infections in their respective late-stage trials.
Moderna said the vaccine's efficacy was consistent across age, race, ethnicity and gender demographics.
Moderna is also claiming that the Phase 3 data shows the vaccine was highly effective at preventing more severe cases of COVID-19. Of the 196 people who contracted Covid-19 out of over 30,000 volunteers, 185 had received a placebo and 11 got the vaccine. Data posted November 16 showed this efficacy at a slightly higher 94.5%, although this was based on 90 cases of COVID-19. The company reported 30 severe cases - all in the placebo group - which means the vaccine was 100% effective at preventing severe cases.
The vaccine deliveries would begin within hours of the authorization, the sources added. "Therefore, it really is quite plausible that the short-term efficacy against severe disease is indeed close to 100%". But it has not caused any significant safety concerns so far, he said. 'JUST OVERWHELMING'Moderna said it was on track to have about 20 million doses of its vaccine ready to ship in the United States by the end of 2020, enough to inoculate 10 million people.
The company's vaccine, known as mRNA-1273, now has data for 196 cases, which Moderna says "confirms the high efficacy observed at the first interim analysis" that came out two weeks back.
Zaks said the vaccine has been developed during a period of "political acrimony" and having a highly effective vaccine may go a long way toward erasing some of that distrust.
"There's a light at the end of the - as of yet - very dark tunnel", he said, "but for the first time since March, I feel hopeful about turning a corner".